With extensive industry expertise, Dark Horse Consulting provides strategic and technical services to help clients realize their goals of bringing therapies to patients and commercialization as featured in Biopharma Dealmakers Go to Article
DHC in the News
New Gene Therapy CMC Guidance from the FDA – A Breakthrough in Regulation or Something More Generic?
An in depth analysis and recommendations for the recently revised cell & gene therapy guidances from our founder and CEO, Anthony Davies, was featured in an editorial for Cell & Gene Therapy Insights.
Experts from North American and European organisations are also supporting the trade mission. Anthony Davies, Ph.D., CEO of Dark Horse Consulting added, “As the first and only global consulting practice focused on CMC for cell and gene therapy, Dark Horse thoroughly endorses the intent of this trade mission. We also welcome the ISCT’s participation as a
CellGenix, a global leader in providing GMP-grade raw materials for cell and gene therapy and tissue-engineered products, today announced the appointment of highly experienced and internationally respected experts in the field of cell and gene therapy to its Scientific Advisory Board (SAB). The SAB will serve as a strategic resource to CellGenix as it continues